What Contract Research Partners Are Best for Running Decentralized or Hybrid Clinical Trials?

How biotech companies can identify the right CRO partner to accelerate patient recruitment, improve trial quality, reduce operational burden and deliver regulatory-ready data.

The way clinical trials are conducted has changed dramatically over the last five years. What began as a necessity during the COVID-19 pandemic has evolved into a strategic advantage for sponsors seeking faster recruitment, greater patient diversity, improved retention and lower operational costs.

Today, decentralized clinical trials (DCTs) and hybrid clinical trials are no longer niche approaches. They have become an important part of modern clinical development strategies across rare diseases, respiratory disorders, neurology, oncology, metabolic disorders and chronic diseases.

The global decentralized clinical trials market is projected to reach USD 10.92 billion in 2026 and is expected to grow to USD 29.37 billion by 2034, reflecting a CAGR of 13.2% as sponsors increasingly adopt hybrid, technology-enabled and patient-centric clinical trial models.

For emerging biotech companies, however, implementing a decentralized study isn't simply about adding telemedicine or wearable devices. Success depends heavily on choosing the right Contract Research Organization (CRO).

This article explores what are decentralized clinical trials, the qualities sponsors should look for in CRO partners, common misconceptions, evolving regulatory expectations and how the right partner can transform a complex decentralized program into a successful clinical study.

What Are Decentralized Clinical Trials?

A decentralized clinical trial is a clinical study where some, or all, trial activities occur outside traditional investigator sites. Instead of requiring participants to travel repeatedly to hospitals or research centers, decentralized studies leverage technologies and local healthcare resources, including:

• Telemedicine visits
• Home nursing
• Electronic informed consent (eConsent)
• Wearables
• Remote patient monitoring
• Electronic patient-reported outcomes (ePRO)
• decentralized clinical trials and eCOA (electronic Clinical Outcome Assessments)
• Direct-to-patient drug shipment
• Local laboratories and imaging centers

Hybrid studies combine traditional site visits with decentralized elements, offering greater flexibility while maintaining protocol integrity. The FDA's finalized guidance on conducting clinical trials with decentralized elements recognizes these approaches and provides recommendations on maintaining participant safety, data quality and regulatory compliance.

Why Biotech Companies Are Rapidly Adopting Decentralized Clinical Trials

Emerging biotech companies face unique operational challenges:

• Limited funding
• Lean clinical operations teams
• Pressure to reach milestones quickly
• Investor expectations
• Competition for study participants
• Limited global infrastructure

Traditional site-centric trials often struggle with:

• Slow recruitment
• High screen failure rates
• Participant dropouts
• Geographic limitations
• Rising operational costs

This explains the growing interest in the decentralized clinical trial model, which enables sponsors to reach patients where they live rather than expecting patients to travel to research sites. Recent industry analyses also suggest that decentralized approaches can significantly improve development efficiency and, when appropriately implemented, increase the economic value of clinical programs through improved enrollment and retention.

The Benefits of Decentralized Clinical Trials

When executed properly, the benefits of decentralized clinical trials extend far beyond patient convenience.

• Faster Patient Recruitment
  Patients from rural and underserved regions become eligible without extensive travel. This expands recruitment pools considerably.
• Better Participant Retention
  Frequent travel is one of the leading causes of participant withdrawal. Remote visits, local laboratory testing, home healthcare visits and digital engagement reduce patient burden.
• Improved Diversity
  Decentralized recruitment improves representation across geography, ethnicity, socioeconomic status and age groups, an increasingly important regulatory consideration.
• Higher Quality Longitudinal Data
  Wearables, remote monitoring devices, mobile applications and decentralized clinical trials and eCOA solutions enable continuous data capture rather than periodic site visits.
  This often results in richer datasets and better understanding of treatment effects.
• Lower Operational Costs
  Sponsors may reduce:
  • Site overhead
  • Travel reimbursements
  • Monitoring costs
  • Administrative workload
  • while maintaining protocol compliance.
• Greater Patient Engagement
  Patients increasingly expect healthcare experiences similar to other digital services. Remote interactions improve convenience and participant satisfaction.

Choosing Among Decentralized Clinical Trials Companies

Not every CRO claiming decentralized capabilities actually possesses the operational maturity required. Many organizations simply outsource technology vendors without integrating them into study operations.

The best decentralized clinical trials companies combine technology, operational expertise, medical oversight, regulatory knowledge and data management into a unified delivery model.

Key evaluation criteria include:

1. Full-Service Clinical Operations

A CRO should manage:

• Study start-up
• Site selection
• Regulatory submissions
• Project management
• Clinical monitoring
• Medical monitoring
• Pharmacovigilance
• Database management
• Biostatistics
• Medical writing

Fragmented vendors often create communication gaps.

Integrated CROs reduce operational complexity.

2. Hybrid Trial Expertise

Very few trials today are fully decentralized.

Most studies require:

• Investigator visits
• Local healthcare providers
• Home healthcare
• Telemedicine
• Traditional monitoring

An experienced CRO understands how to combine centralized and decentralized workflows effectively.

3. Flexible Technology Ecosystem

Technology should support the study.

Look for partners capable of integrating:

• eConsent
• ePRO
• eCOA
• Wearables
• Telehealth
• Remote monitoring
• Patient engagement tools
• Risk-based monitoring dashboards

4. Regulatory Experience

Strong CROs understand evolving decentralized clinical trials guidance across major regulatory agencies.

Current FDA recommendations emphasize maintaining participant safety, investigator oversight, protocol adherence, data integrity and appropriate documentation when implementing decentralized trial elements. (U.S. Food and Drug Administration)

5. Data Management Excellence

Remote data collection creates large volumes of information from multiple sources.

Your CRO should possess expertise in Clinical Data Management, Statistical Programming, Biostatistics, Data Standardization and Medical Writing without relying on multiple disconnected vendors.

Common Decentralized Clinical Trial Myths

Despite growing adoption, several misconceptions remain.

Myth 1: Decentralized Means No Study Sites
Reality:
Most modern trials are hybrid. Investigative sites remain essential for procedures requiring specialized equipment or physician oversight.

Myth 2: Technology Solves Everything
Reality:
Technology is only one component.
Successful DCTs require experienced project management, trained investigators, regulatory oversight, patient engagement strategies and integrated data management.

Myth 3: Only Large Pharma Can Run DCTs
Reality:
Biotech companies often benefit the most because decentralized approaches can improve recruitment efficiency while reducing operational burden.

Myth 4: Regulators Don't Support DCTs
Reality:
Regulators increasingly recognize decentralized elements when implemented appropriately.
The FDA's finalized recommendations provide sponsors with practical expectations for decentralized trial conduct while emphasizing patient safety, data reliability, and investigator responsibilities. (U.S. Food and Drug Administration)

What Biotech Sponsors Should Look for in Their CRO Partner

For emerging biotechnology companies, selecting the right Contract Research Organization (CRO) is about choosing a strategic partner that can help accelerate drug development while minimizing risk. The ideal CRO should offer executive-level engagement, providing direct access to experienced leadership and scientific experts who can guide critical decisions throughout the study lifecycle. Equally important are flexible operating models that can scale alongside evolving program needs, supported by deep expertise in global regulatory requirements, integrated clinical operations, clinical data management, biostatistics, medical writing and pharmacovigilance.

As decentralized and hybrid trials become increasingly data-driven, sponsors should also seek partners with capabilities in real-world evidence generation and AI-enabled clinical analytics that can transform complex datasets into actionable insights. The right CRO becomes an extension of the biotech’s team, enabling faster, higher-quality clinical development while reducing operational complexity and supporting long-term program success.

How Navitas Life Sciences Supports Modern Decentralized and Hybrid Clinical Trials

For biotech companies, selecting the right CRO is about finding a partner that can seamlessly integrate decentralized capabilities into a broader clinical development strategy. Navitas Life Sciences recognizes that successful decentralized and hybrid clinical trials require far more than digital tools, they demand scientific expertise, operational excellence, flexible delivery models and strong governance.

As a full-service, technology-enabled CRO, Navitas supports sponsors across the entire clinical development lifecycle, from Phase I through Phase IV clinical trials. Our integrated capabilities include Clinical Trial Operations, BA/BE studies, medical monitoring, regulatory affairs, pharmacovigilance, clinical data management, biostatistics, statistical programming, clinical data standardization and medical writing.

 

Our approach is built around executive-level engagement, giving sponsors direct access to experienced scientific and operational leaders who provide strategic guidance, rapid decision-making and hands-on support throughout the study. Rather than functioning as a transactional service provider, we work as a true extension of our clients' teams, developing customized engagement models that evolve alongside changing program requirements.

Our proprietary OneClinical Analytics platform provides near real-time visibility into study performance, for faster decisions, improve oversight and proactively addressing potential issues before they impact study timelines.

Equally important is our commitment to flexibility and accountability. We design customized engagement models that provide transparent governance, scalable resourcing, outcome-focused delivery and operational accountability with minimal sponsor oversight.

Whether supporting a lean biotech preparing for first-in-human studies or an established pharmaceutical company running multinational hybrid trials, our teams adapt to changing regulatory requirements, recruitment demands and development priorities for faster market reach.

 

Learn more about our services and solutions by reaching out to us at This email address is being protected from spambots. You need JavaScript enabled to view it..